Dr. Brigitte Widemann with NF1 patient Travis Carpenter
Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and children experienced reduced pain, improved function, and better overall quality of life after receiving the treatment.
Read more: www.nih.gov/news-events/news-releases/nih-trial-selumetin...
In this image: Dr. Brigitte Widemann with Travis Carpenter, who received selumetinib for NF1 at NIH.
Credit: National Cancer Institute, NIH
Dr. Brigitte Widemann with NF1 patient Travis Carpenter
Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and children experienced reduced pain, improved function, and better overall quality of life after receiving the treatment.
Read more: www.nih.gov/news-events/news-releases/nih-trial-selumetin...
In this image: Dr. Brigitte Widemann with Travis Carpenter, who received selumetinib for NF1 at NIH.
Credit: National Cancer Institute, NIH